Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Definitive Healthcare (DH) Cash & Equivalents (2020 - 2026)

Definitive Healthcare filings provide 6 years of Cash & Equivalents readings, the most recent being $163.6 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 55.28% to $163.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $163.6 million, a 55.28% increase, with the full-year FY2025 number at $163.6 million, up 55.28% from a year prior.
  • Cash & Equivalents hit $163.6 million in Q4 2025 for Definitive Healthcare, up from $108.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $387.5 million in Q4 2021 to a low of $77.5 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $131.7 million (2023), compared with a mean of $155.9 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 1464.13% in 2021 and later crashed 66.15% in 2023.
  • Definitive Healthcare's Cash & Equivalents stood at $387.5 million in 2021, then crashed by 62.08% to $146.9 million in 2022, then fell by 10.86% to $131.0 million in 2023, then decreased by 19.54% to $105.4 million in 2024, then surged by 55.28% to $163.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $163.6 million (Q4 2025), $108.3 million (Q3 2025), and $81.0 million (Q2 2025) per Business Quant data.